Efficacy and Safety Variables in Clinical Study Report
ICH E3 Section 9.5 calls for identification of the efficacy and safety variables assessed, the methods and timing of assessments, and the people or procedures responsible for measurements, often with a schedule or flow chart. This section defines variables and assessment methods; it is not the same artifact as the later efficacy or safety result tables.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
Use this section to define what efficacy and safety outcomes were measured, how they were measured, and when assessments occurred.
Key details
Core IssueICH E3 Section 9.5 calls for identification of the efficacy and safety variables assessed, the methods and timing of assessments, and the people or procedures responsible for measurements, often with a schedule or flow chart.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This section defines variables and assessment methods; it is not the same artifact as the later efficacy or safety result tables.
Further guidance
Content
Specify the variables, assessment methods, timing, and relevant measurement responsibilities so later analyses and tables can be interpreted against the prespecified study design.
Purpose
Use this section to define what efficacy and safety outcomes were measured, how they were measured, and when assessments occurred.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 9.5.3 calls for the primary efficacy variable or variables to be specified and for their role in evaluating efficacy to be clear. This page is limited to the planned primary-efficacy-variable subsection; detailed statistical analysis belongs in the statistical-methods and efficacy-results sections.
ICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives. This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
ICH E3 Section 13 calls for a concise discussion of efficacy and safety results, the risk-benefit relationship, unexpected findings, clinical relevance, unresolved issues, and implications for future studies without merely repeating results or introducing new ones. This section interprets results already presented; it should not simply duplicate result tables and should not introduce new study results that were not reported elsewhere.
ICH E3 section 11.4.4 addresses relationships among dose, measured drug concentration, and clinical response when those data are relevant to interpreting efficacy. This results-level relationship analysis is distinct from documenting how doses were selected or how concentrations were measured during study conduct.
ICH E3 section 11.4.5 calls for efficacy discussion of drug-drug and drug-disease interactions when they are relevant to the study findings. Do not turn the subsection into a general pharmacology interaction catalogue; keep it tied to interactions evaluated or observed in the reported clinical study.
ICH E3 section 11.4.7 provides a dedicated place for efficacy conclusions after the detailed efficacy analyses and supporting displays. Do not use the conclusion to overrule the detailed analyses or convert exploratory findings into confirmed primary results.
ICH E3 section 11.4.2.6 calls for efficacy analyses in relevant patient subsets to be presented or discussed when subgroup evidence is important to interpretation. Keep a defined efficacy subset distinct from the primary analysis population and from exploratory subgroup claims that require their own interpretation.
ICH E3 reserves section 14.2 for efficacy tables, figures, and graphs referred to in the report but not included in the main text, allowing detailed displays to support the core efficacy analysis. This page is about supporting ICH E3 efficacy displays, not the broader Efficacy Results section that explains analyses and interprets findings in the report body.
